| 5/2/2022 | Coverage of the COVID-19 Vaccination for Medicare Advantage Members (Updated May 2, 2022) | 0.1 | | The purpose of this communication is to provide notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for Medicare Advantage members.
| Coverage of the COVID-19 Vaccination for Medicare Advantage Members (Updated May 2, 2022) | 66bbdfb3-da85-412f-83c9-5c287c6c1a6e |
| 4/27/2022 | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated April 27, 2022) | 0.1 | | The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage members. | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated April 27, 2022) | b23ef10a-9791-4b33-b81a-61bcbf17cfaa |
| 4/25/2022 | Preventive Coverage of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine for Medicare Advantage Members | 0.1 | | The purpose of this communication is to provide notice regarding the expanded preventive coverage criteria for 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine for Medicare Advantage members effective July 1, 2021.
| Preventive Coverage of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine for Medicare Advantage Members | 434e6fa8-8072-42a2-bd17-e1f8f39db5c1 |
| 4/12/2022 | 04/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated April 12, 2022) | 0.1 | | The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 04/01/2022, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable. | 04/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated April 12, 2022) | b2128b73-f094-40fc-bc15-6c2e4f19ac80 |
| 3/21/2022 | Expanded Preventive Coverage for Lung Cancer Screening with Low Dose Computed Tomography | 0.1 | | The purpose of this communication is to provide notice regarding the expanded preventive coverage criteria for lung cancer screening with low dose computed tomography for Independence Medicare Advantage members effective February 10, 2022.
| Expanded Preventive Coverage for Lung Cancer Screening with Low Dose Computed Tomography | 548f88be-de3e-45a9-98e2-771913b847ed |
| 12/31/2021 | Aduhelm™ (aducanumab-avwa) injection for Medicare Advantage Members (Updated January 1, 2022) | 0 | | The purpose of this communication is to provide notification of the Company's position for Aduhelm™ (aducanumab-avwa) injection for all Medicare Advantage products effective June 7, 2021.
| Aduhelm™ (aducanumab-avwa) injection for Medicare Advantage Members (Updated January 1, 2022) | 27115fc7-1143-4662-9686-b4d5db0f6acf |
| 12/31/2021 | Telehealth Services for Medicare Advantage Members | 0.1 | | The purpose of this document is to provide advance notice regarding coverage for telehealth services for our Medicare Advantage members in response to Coronavirus Disease 2019 (COVID-19). | Telehealth Services for Medicare Advantage Members | f4aa34e8-11ba-4eee-81de-bf2f7e35e721 |
| 12/31/2021 | 01/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated January 7, 2022) | 0.1 | | The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 01/01/2022, unless otherwise noted. | 01/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated January 7, 2022) | caa20a02-9c8b-4daf-981c-1acac3da57b1 |
| 12/7/2021 | Changes for COVID-19 Vaccination and Pharmaceutical Treatments for Medicare Advantage Members to Become Effective January 1, 2022 | 0.1 | | The purpose of this communication is to provide advance notification of changes for COVID-19 vaccination and pharmaceutical treatment of COVID-19 scheduled to become effective on January 1, 2022 for Medicare Advantage members.
| Changes for COVID-19 Vaccination and Pharmaceutical Treatments for Medicare Advantage Members to Become Effective January 1, 2022 | 645e03c4-2c9d-4325-99f0-afa969c0f8cb |
| 10/1/2021 | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | 0.1 | | The intent of this article is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2021, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable. | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | da4807d7-c8e8-4da3-adb7-5a156ce37fc4 |
| 6/4/2021 | Notification of Upcoming Changes to Temporary COVID-19 Waivers of Certain Requirements Related to Respiratory Equipment and Related Supplies | 0.1 | | The purpose of this communication is to provide advance notice regarding the reinstatement of certain pre-PHE requirements/limits related to respiratory equipment/related supplies. | Notification of Upcoming Changes to Temporary COVID-19 Waivers of Certain Requirements Related to Respiratory Equipment and Related Supplies | f0cd547c-047a-4d87-9d85-8a03d1d77946 |
| 4/1/2021 | 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | 0.1 | | The intent of this article is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 4/1/2021, unless otherwise noted.
| 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | d2c73a29-4d27-43bb-be4a-15bcdcf54a84 |
| 1/4/2021 | 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Medicare Advantage Products | 0 | | The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Annual Code Update process.
| 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Medicare Advantage Products | 83b993ed-7be0-47bc-983e-86d958abfdc6 |
| 10/22/2020 | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (April 28, 2022) | 0.1 | | The purpose of this document is to communicate the Company's coverage position for Pharmaceutical Treatment of COVID-19 for Independence Medicare Advantage members.
| Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (April 28, 2022) | a7aed5bb-1dd4-43ae-bb68-13d35ea1520f |
| 6/30/2020 | Waiver of certain requirements during COVID-19 outbreak related to Durable Medical Equipment (DME), prosthetics, orthotics, and supplies for Medicare Advantage members (Updated December 15, 2021)
| 1 | | The purpose of this News Article is to provide advance notice regarding the temporary waiver of certain requirements for Durable Medical Equipment (DME), as well as prosthetics, orthotics, and supplies in response to Coronavirus Disease 2019 (COVID-19). | Waiver of certain requirements during COVID-19 outbreak related to Durable Medical Equipment (DME), prosthetics, orthotics, and supplies for Medicare Advantage members (Updated December 15, 2021) | 731A7A410AA02BF08525858B0060F43F |
| 4/29/2020 | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (Updated December 15, 2021)
| 1 | | The purpose of this News Article is to provide advance notice regarding direct supervision requirements for Incident to services performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in response to Coronavirus Disease 2019 (COVID-19). | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 | 4FDDC2AFA5B549C885258558007D7B93 |
| 4/14/2020 | Ground Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated December 15, 2021)
| 0 | |
The purpose of this communication is to provide advance notice regarding the temporary expansion of the list of allowable destinations for ground ambulance transports AND to convey coverage criteria for medically necessary ground ambulance services without a transport in response to the Public Health Emergency (PHE) for the COVID-19 pandemic. | Ground Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated December 15, 2021) | f43a2ed7-486a-48bf-bb49-fa849eb03cfb |
| 4/14/2020 | Medicare Diabetes Prevention Program in Response to COVID-19 Outbreak (Updated December 15, 2021) | 0.1 | | The purpose of this NewsFLASH is to provide advance notice regarding coverage for Medicare diabetes prevention program in response to Coronavirus Disease 2019 (COVID-19).
| Medicare Diabetes Prevention Program in Response to COVID-19 Outbreak (Updated December 15, 2021) | 4d8e7d77-5a72-4739-96cc-d1c17590ac58 |
| 9/9/2015 | Clarification Regarding Coverage for the VisibiliT™ Test
| 1 | | The purpose of this article is to communicate that the VisibiliT™ test (represented by procedure code 0009M) is medically necessary with criteria since this code's effective date of 07/01/2015. This communication supersedes any previous communications for 0009M from the Company. | Clarification Regarding Coverage for the VisibiliT™ Test | 3868AC77FDADAF3B85257EBB005F4A43 |
